Barclays PLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 294.2% during ...

EDP-235 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer ...

Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Technical analysis for Enanta Pharmaceuticals Inc. ENTA including support levels resistance levels and stop losses for ENTA ...

Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Enanta Pharmaceuticals (ENTA – Research Report). The associated price target remains the same with $21.00. Pick the ...

Enanta Pharmaceuticals (ENTA) shares rallied 7.2% in the last trading session to close at $6.28. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

Enanta Pharmaceuticals (ENTA) announced that the United States District Court of Massachusetts has issued a ruling on a summary judgment motion ...